Skip to content
POM-V Prescription Required Companion Animal

Dexacortone 2.0 mg Chewable Tablets for Dogs and Cats

Active ingredient: Dexamethasone

Form

Chewable

Species

Cats Dogs

Manufacturer

Le Vet Beheer B.V.

VMD MA No.

41821/5022

What it's used for

For the symptomatic treatment or as adjunct treatment of inflammatory and allergic conditions in dogs and cats.

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Dexamethasone

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Dexacortone 2.0 mg Chewable Tablets for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For the symptomatic treatment or as adjunct treatment of inflammatory and
allergic conditions in dogs and cats.
Do not use in animals with viral or mycotic infections.
Do not use in animals with diabetes mellitus or hyperadrenocorticism.
Do not use in animals with osteoporosis.
Do not use in animals with cardiac or renal dysfunction.
Do not use in animals with corneal ulcers.
Do not use in animals with gastro-intestinal ulceration.
Do not use in animals with burns.
Do not use concomitantly with attenuated alive vaccine.
Do not use in the case of glaucoma.
Do not use during pregnancy (see section 4.7).

Revised: August 2025
AN: 01855/2023
Do not use in cases of hypersensitivity to the active substance, to
corticosteroids or to any of the excipients.
See also section 4.8.
Dogs and cats:
Very common
(>1 animal / 10 animals
treated):
Cortisol suppression
, elevated triglyceride
Rare
(1 to 10 animals / 10,000
animals treated):
Elevated liver enzymesUndetermined frequency
(cannot be estimated from the
available data):
Polyphagia
, polydipsia
Polyuria
Hyperadrenocorticism (Cushings disease)
4,5
,
Diabetes mellitus
Excitation
Gastrointestinal ulceration
, pancreatitis
Enlarged liver (hepatomegaly)
Changes in blood biochemical and
haematological parameters (e.g. elevated
serum alkaline phosphatase (SAP),
decreased lactic acid dehydrogenase (LDH),
hyperalbuminaemia, eosinopenia,
lymphopenia, neutrophilia
, decreased
aspartate aminotransferase).
Hypothyroidism, elevated parathyroid (PTH)
concentration
Inhibition of longitudinal growth of bones
Cutaneous calcinosis, skin thinning
Delayed healing, immunosuppression
,
weakened resistance to or exacerbation of
existing infections
Sodium and water retention
, hypokalaemia
1
as a result of effective doses suppressing the hypothalamic-pituitary-adrenal
axis.
as part of possible iatrogenic hyperadrenocorticism (Cushings disease).
after systemic administration and particularly during early stages of therapy.

Revised: August 2025
AN: 01855/2023
iatrogenic.
involving significant alteration of fat, carbohydrate, protein and mineral
metabolism, e.g. redistribution of body fat, increase in body weight, muscle
weakness and wastage and osteoporosis may result.
may be exacerbated by steroids in animals given non-steroidal anti-
inflammatory drugs and in animals with spinal cord trauma.
increase of segmented neutrophils.
in the presence of viral infections, corticosteroids may worsen or hasten the
progress of the disease.
in long-term use.
Anti-inflammatory corticosteroids, such as dexamethasone, are known to exert
a wide range of side effects. Whilst single high doses are generally well
tolerated, they may induce severe side-effects in long-term use. Long-term use
should therefore be avoided. Should long-term use be indicated, a corticosteroid
with a shorter duration of action e.g. prednisolone is more appropriate (see
section 4.5).
Following cessation of treatment, signs of adrenal insufficiency extending to
adrenocortical atrophy can arise and this may render the animal unable to deal
adequately with stressful situations. Consideration should therefore be given to
means of minimising problems of adrenal insufficiency following the withdrawal
of treatment.
See also section 4.7.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or the national competent authority via
the national reporting system. See the package leaflet for respective contact
details.
Corticoid administration is to induce an improvement in clinical signs rather than
a cure. The treatment should be combined with treatment of the underlying
disease and/or environmental control.

Special precautions for use in animals
In cases where it has been deemed necessary to administer the veterinary
medicinalproduct in the presence of bacterial, parasitic or fungal infection, the
underlying infection should be treated concomitantly with suitable antibacterial,
antiparasitic or antifungal therapy.
Because of the pharmacological properties of dexamethasone, special care
should be taken when the veterinary medicinal product is used in animals with a
weakened immune system.
Corticoids such as dexamethasone, exacerbate proteinaceous catabolism.
Consequently, the veterinary medicinal product should be used with caution in
old or malnourished animals.
Corticoids such as dexamethasone should be used with caution in patients with
hypertension.
Since glucocorticoids are known to slow growth, use in young animals (under 7
months of age) should be based on a benefit/risk assessment by the attending
veterinarian.
Pharmacologically-active dose levels may lead to atrophy of the adrenal cortex,
resulting in adrenal insufficiency. This may become apparent particularly after
withdrawal of corticosteroid treatment. The dosage should be reduced and
withdrawn gradually to avoid precipitation of adrenal insufficiency.
Avoid long-term use with oral corticosteroids whenever possible. Should long-
term use be indicated, a corticosteroid with a shorter duration of action e.g.
prednisolone is more appropriate. With prednisolone, alternate-day therapy can
be utilised for longer-term use to minimise adrenal insufficiency. Due to the long
duration of effect of dexamethasone alternate day therapy is not an adequate
way to allow the hypothalamic-pituitary-adrenal axis to recover (see section
4.9).
The tablets are flavoured. In order to avoid any accidental ingestion, store
tablets out of reach of animals.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Dexamethasone may cause hypersensitivity (allergic) reactions. Skin contact
with the veterinary medicinal product should be avoided, especially in people
with known hypersensitivity to dexamethasone or any of the excipients (e.g.
povidone or lactose). Wash hands after use. Seek medical advice in case of
hypersensitivity reactions.
This veterinary medicinal product may be harmful to children after accidental
ingestion. Do not leave the veterinary medicinal product unattended. Return

Revised: August 2025
AN: 01855/2023
unused part-tablets to the blister pack and use them on the next administration.
Keep the blister in the outer carton to prevent access by children. In case of
accidental ingestion seek medical advice immediately and show the package
leaflet or the label to the physician.
Dexamethasone can cause harm to unborn children. Pregnant women should
avoid exposure. Absorption through the skin is negligible but it is recommended
to immediately wash hands after handling the tablets to avoid hand-to-mouth
contact.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.
Phenytoin, barbiturates, ephedrine and rifampicin, may accelerate the metabolic
clearance of corticosteroids resulting in decreased blood levels and reduced
physiological effect.
The concomitant use of this veterinary medicinal product with non-steroidal anti-
inflammatory drugs may exacerbate gastrointestinal tract ulceration. Because

Revised: August 2025
AN: 01855/2023
corticosteroids can reduce the immunoresponse to vaccination, dexamethasone
should not be used in combination with vaccines or within two weeks after
vaccination.
Administration of dexamethasone may induce hypokalaemia and hence
increase the risk of toxicity from cardiac glycosides. The risk of hypokalaemia
may be increased if dexamethasone is administered together with potassium
depleting diuretics.
Return unused part-tablets to the blister pack and use them on the next
administration. Do not store above 30 ºC. Keep the blisters in outer carton in
order to protect from light.

Revised: August 2025
AN: 01855/2023
Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.